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We describe a novel localization of C7 as
a membrane-bound molecule on endothe-
lial cells (ECs). Data obtained by sodium
dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS-PAGE), Western blot
analysis, Northern blot analysis, and mass
spectrometry revealed that membrane-
associated C7 (mC7) was indistinguish-
able from soluble C7 and was associated
with vimentin on the cell surface. mC7
interacted with the other late complement
components to form membrane-bound
TCC (mTCC). Unlike the soluble SC5b-9,
mTCC failed to stimulate ECs to express
adhesion molecules, to secrete IL-8, and
to induce albumin leakage through a
monolayer of ECs, and more importantly
protected ECs from the proinflammatory
effect of SC5b-9. Our data disclose the
possibility of a novel role of mC7 that acts
as a trap for the late complement compo-
nents to control excessive inflammation
induced by SC5b-9. (Blood. 2009;113:
3640-3648)
Introduction
The endothelium is organized into a monolayer of cells that cover
the luminal side of the blood vessels along the vascular tree
forming a physical barrier between circulating blood and the
surrounding tissue. An important role of endothelial cells (ECs) of
microvessels is to control the passage of soluble molecules and to
regulate the migration of blood leukocytes into the extravascular
sites in response to a variety of perturbing agents. Activation of
ECs sets in motion a multistep process associated with sequential
expression of adhesion molecules leading the leukocytes to adhere
to ECs, to spread out on their surface, and eventually to egress into
the surrounding tissue crawling through the interendothelial
junctions.1,2
A large number of molecules including bacterial products, such
as lipopolysaccharides (LPS), cytokines, and chemokines, have
been shown to stimulate ECs and to contribute to the development
of the inflammatory process.3 Among the proinflammatory mol-
ecules, a special role is played by the biologically active products
of the complement (C) system that are released systemically or
locally as a result of C activation through the classical, the
alternative, or the lectin pathway. The terminal C complex (TCC) is
one of these products that has received special attention for its
ability to interact with ECs and to cause vascular changes in
pathologic conditions associated with ischemia-reperfusion and
vasculitis.4 TCC is formed by the assembly of C5b and the
remaining late components on the cell surface after C activation by
cell-bound antibodies or other non-antibody C-activating sub-
stances.5 This complex may insert into the cell membrane as a
cytolytic membrane attack complex (MAC), but more often binds
to EC surface as a sublytic complex.
A large proportion of the terminal complex is formed in various
pathologic conditions including bacterial sepsis, immune complex-
mediated diseases, traumata, ischemia-reperfusion, and others that
are associated with massive C activation. Assembly of this complex
on ECs in a lytic form may cause extensive cell damage, while
insertion of the same complex in a sublytic form induces persistent
stimulation of the endothelium and marked inflammatory reaction.
Despite the inability to cause cytotoxic cell damage, the sublytic
complex is still able to stimulate ECs to express P-selectin,6 to
release interleukin-1 (IL-1) and to enhance the stimulating effect of
tumor necrosis factor- (TNF-) on the expression of adhesion
molecules.7 This complex has also been shown to trigger the coagulation
process by promoting the assembly of prothrombinase complex and the
expression of tissue factor, and contributes to the changes in the vascular
tone by inducing the release of the vasodilator prostacyclin PGI28 and
the vasoconstrictor thromboxane A2.9
To neutralize the damaging effects of MAC, ECs express on
their surface CD59, which inhibits the oligomerization of C9 thus
preventing the assembly of MAC.10,11 It should be emphasized that
CD59 does not provide full protection from an excessive amount of
MAC, and, in addition, fails to control the stimulating activity of
the cytolytically inactive TCC released in the circulation under
conditions of unrestricted C activation. Assembly of this complex
starts with the formation of C5b6 complex, which is then stabilized
by the binding of C7. However, the trimolecular complex C5b-7
has only a transient ability to insert into the phospholipid bilayer of the
cell membrane.12,13 Should this not occur within few milliseconds,
C5b-7 still maintains the ability to bind the remaining terminal
components and forms a nonlytic terminal complex C5b-9 containing
the soluble C regulators S-protein and clusterin (SC5b-9).12,14 Despite
the inability to cause cytolysis, SC5b-9 has been shown to bind to ECs
and to induce expression of adhesion molecules, production of cyto-
kines, and vascular leakage.15,16
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We now report an additional protective mechanism of ECs from
the proinflamatory effects of SC5b-9. The protection is provided by
C7 expressed on the cell membrane as a functionally active
molecule that reacts with activated C5b6 and the remaining late
components to form membrane-bound TCC (mTCC). Evidence
will also be presented suggesting that this complex, unlike the
soluble SC5b-9, fails to stimulate ECs acting as a trap for the
assembling TCC and down-regulates the activation of these cells
induced by the soluble complex.
Methods
Reagents
Components C5 to C9, goat antisera to C3 and to the late C components
from C6 to C9, monoclonal antibodies (mAbs) to human C3, C7, and
clusterin were purchased from Quidel (San Diego, CA); mAb to human
S-protein was obtained from Chemicon (Billerica, MA). The immunoglobu-
lin G (IgG) was purified from the antisera by affinity chromatography on
protein G-Sepharose column (GE Healthcare, Piscataway, NJ). The mAb
aE11 recognizing a neoantigen expressed in poly(C9) was from Dako
(Glostrup, Denmark) and mAb anti-C7 (WU 4-15) was previously re-
ported.17 Anti-VCAM mAb P3C4 was from Chemicon, anti–E-selectin
CBL180 from Cymbus Biotechnology (Southampton, United Kingdom),
and anti–ICAM-1 6.5B5 from Dako, and all were used at a final
concentration of 5 g/mL. Anti–vimentin polyclonal and mAb V9 was
purchased from Sigma-Aldrich (St Louis, MO).
The following secondary antibodies were used: fluorescein isothiocya-
nate (FITC)–conjugated F(ab)2 fragment of goat anti–mouse Ig were from
Dako; biotin-labeled rabbit anti–mouse IgG, alkaline-phosphatase (AP)–
conjugated goat IgG directed to mouse IgG or rabbit anti–goat IgG, and
AP-conjugated streptavidin were purchased from Sigma-Aldrich.
Heparinases I, II, and III were from Sigma-Aldrich. Human recombi-
nant TNF-, IL-1, and interferon- (IFN-) were purchased from
PeproTech (Rocky Hill, NJ) and were used at a concentration of 100 ng/mL,
10 U/mL, and 100 U/mL, respectively.
Assembly of soluble and membrane-bound TCC
SC5b-9 was prepared as previously described15 and used at a final
concentration of 5 g/mL.
The mTCC was assembled on human umbilical vein endothelial cells
(HUVECs) grown to confluence in 96-well plates by incubating the cells
with 2 g C5b6 for 10 minutes at 37°C and then with 1 g C8 and 2 g C9
to a final volume of 100 L for 2 hours at 37°C. The presence of mTCC was
evaluated by enzyme-linked immunosorbent assay (ELISA) on whole cells
using mAb aE11. A similar approach was followed to assemble SC5b-9 on
affinity-purified mC7 (see below) using C5b-6 and C7-deficient serum as a
source of C8, C9, S-protein, and clusterin.
Cells and cell line
HUVECs were isolated by collagenase treatment and cultured in medium
199 supplemented with 20% newborn calf serum (Invitrogen, Carlsbad, CA),
50g/mLendothelial growth supplement, 50g/mLheparin, 100 U/mLpenicil-
lin, and 100g/mL streptomycin (Sigma-Aldrich) as previously published.18
HepG2 cells (hepatocellular carcinoma cell line) and human B-lymphocyte cell
line Raji, obtained from the ATCC (Manassas, VA), were grown in RPMI 1640
supplemented with 10% fetal calf serum (FCS) and 1% antibiotic-antimycotic
solution (Invitrogen).
ELISA
The amount of C3 and C7 released in the supernatant of EC culture and on
whole cells was measured by ELISA as previously reported.18-20 The level
of IL-8 was measured by ELISA using a commercial kit (Biosource
International, Camarillo, CA).
Flow cytometry
HUVECs (5  105) were incubated with primary antibodies for 1 hour at
37°C followed by FITC-conjugated goat F(ab)2 anti–mouse Ig. After
fixation with 1% paraformaldehyde (Sigma-Aldrich), the cells were ana-
lyzed on a FACSCalibur instrument (BD Biosciences, San Jose, CA) using
CellQuest software.
Transmission electron microscopy
The localization of C7 and C3 on HUVECs grown to confluence in
8-chamber culture slides (BD Biosciences) was analyzed using a pre-
embedding technique as previously described.21
Immunohistochemical staining
Sections from paraffin-embedded tissue samples obtained from the archives
of the Department of Human Pathology (University of Palermo, Palermo,
Italy), were analyzed as previously reported.20
Acid strip
The acid strip procedure was performed on HUVECs grown to confluence
in 96-well tissue-culture plates (Costar; Corning, Lowell, MA) according to
Haigler.22 In other experiments, the cells were incubated in phosphate-
buffered saline (PBS) containing 1 or 3 M KCl for 6 minutes at 4°C. The
residual cell-bound C7 was evaluated by ELISA on whole cells (see above).
Immunoaffinity chromatography
HUVECs grown to confluence in 75-cm2 flasks (Costar) were washed and
lysed with 0.5 M octyl -D-glucopyranoside (Sigma-Aldrich) in distilled
water and protease inhibitor cocktail (Sigma-Aldrich). Cell supernatant or
cell lysate was passed through an anti-C7 immunoaffinity column prepared
as described by Langeggen et al,19 and bound C7 was eluted with 4 M
guanidine-HCl (Sigma-Aldrich) in 0.1 M sodium phosphate, pH 7.4,
containing 2 M NaCl.
SDS-PAGE and immunoblotting
Immunopurified products were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions
as previously described.20
RNA isolation and Northern blot analysis
Cultured cells were harvested in Omnizol (Euroclone, Milano, Italy), and
total RNA was extracted according to the supplier’s instructions. The
Northern blot analysis was carried out by the method of Maniatis et al23 The
specific probe C7 (primer sequence: sense, 5-ATGTCAGCGCTGG-
GAGAAACT-3; antisense, 5-CAAGGCCTTATGCTGGTGACA-324 was
32P-labeled by random priming using Ready-To-Go DNA labeling beads
(GE Healthcare) according to the manufacturer’s protocol.
Protein sequencing
Protein bands were excised from SDS-PAGE gels stained with Coomassie
blue. The spots were in-gel–digested with trypsin,25 and the mixture of
recovered tryptic peptides was subjected to nanoelectrospray tandem mass
spectrometry (MS/MS) sequencing essentially as described.26 A similar
approach was followed to analyze tryptic peptides obtained from affinity-
purified C7. Analyses were performed on LTQ mass spectrometer (Thermo
Electron; Thermo Fisher Scientific, Waltham, MA) equipped with a
nanoelectrospray ion source and online coupled to the high-performance
liquid chromatography (HPLC) system. The MS/MS data were searched
against the human International Protein Index (IPI) nonredundant database
(version 3.19) using SORCERER-SEQUEST version 3.0.3, which was run
on the SageN Sorcerer (Thermo Electron). Search results were subjected to
statistical filtering using Peptide Prophet and Protein Prophet (version
3.0).26,27 Peptides with a final P value of .9 or more, which in this case equals
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to a probability of approximately 98% of being correct, were used for all
further analyses.
Antibody capture ELISA
ECs detached from culture plates with 5 mM ethylenediaminetetraacetic
acid (EDTA) were incubated with goat IgG against human C7, C3, or C6 for
1 hour at 37°C and, after washing, were treated with lysis buffer (see
above). The antibody capture ELISA (AC-ELISA) for C7-vimentin com-
plex was performed coating microtiter plates (Corning) with 100 L protein
G (1 g/mL in carbonate buffer, pH 9.5) overnight at 4°C. After washing
and blocking with 2% skimmed milk, 100 L cell lysate were incubated for
1 hour at 37°C, and the captured proteins were detected using goat IgG
anti-vimentin or unrelated antibodies for 1 hour at 37°C and AP-conjugated
anti–goat IgG for 45 minutes at 37°C. The reaction was visualized with
p-nitrophenil phosphate.
EC leakage
The assay was performed following a procedure previously described.16
Statistical analysis
Results were reported as mean plus or minus standard deviation (SD). The
Student t test was used to compare 2 groups of data. Statistical significance
was defined as P value less than .05.
Results
ECs express C7 on their surface
We have previously reported that ECs actively synthesize C7, and
they represent a major site of synthesis of this C component.19
While searching for intracellular localization of C7 by immunoflu-
orescence analysis of ECs, we noted that the cell surface stained for
this C component. This observation prompted us to find more
compelling evidence for the surface expression of C7 and its
functional role. Our first approach was to analyze the supernatants
of HUVECs grown to confluence in 96-well culture plates for the
presence of C7 by ELISA using goat IgG anti-C7 and goat IgG
anti-C3, as a control. The data presented in Figure 1A confirmed
our previous finding that ECs secrete both C3 and C7, but in
addition, they show that HUVECs express a high amount of C7 on
their surface, whereas C3 is undetectable. Similar results were
obtained using 2 different mAbs to C7 (data not shown) and
fluorescence-activated cell sorting (FACS) analysis confirmed the
surface expression of C7 on HUVECs (Figure 1B).
To further document the presence of C7 on the cell surface,
HUVECs grown to confluence in 8-chamber culture slides were
incubated with mAbs to human C3 or C7 followed by biotinylated
secondary antibodies and gold-labeled streptavidin. The cells were
then analyzed under a transmission electron microscope. Colloidal
gold particles were clearly visible on EC membrane stained for C7,
but not on cells analyzed for C3 (Figure 1C). To further extend
these observations, we analyzed human biopsy specimens from
normal skin, brain, kidney, endometrium, and decidua by immuno-
peroxidase and found that goat IgG anti-C7 stained ECs of the
blood vessels in all tissues examined (Figure 2).
Characterization of membrane C7
The immunoenzymatic detection of a substantial amount of C7 on
ECs led us to investigate whether cell-associated C7 may derive
Figure 1. Presence of C7 on the endothelial cells
surface. (A) The amount of C7 and C3 secreted by
HUVECs grown to confluence was measured by ELISA
in the culture supernatant. The presence of C7 and C3
on the cell membrane was evaluated by ELISA on whole
cells using biotin-labeled goat antibodies to C7 or C3
(5 g/mL), followed byAP-labeled streptavidin. (B) FACS
analysis of nonpermeabilized HUVECs for surface ex-
pression of mC7 using mAbs anti-C7 (black line),
anti-C3 (gray line; 10 g/mL), and irrelevant IgG (dotted
line) followed by FITC-labeled goat anti–mouse IgG.
(C) TEM analysis of HUVECs incubated with mAb
anti-C3 or anti-C7 (both used at 1:50) followed by
biotinylated secondary antibodies and gold-labeled
streptavidin. Magnification bar represents 200 nm.
One of 3 experiments with similar results is shown.
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from soluble C7 captured by the cells after secretion. To address
this issue, a confluent monolayer of ECs was incubated with
affinity-purified membrane-bound C7 (mC7) or soluble C7 for
2 hours at 37°C, and bound C7 was revealed by ELISA. Under
these experimental conditions, we failed to detect binding of C7 to
ECs (data not shown). An alternative possibility was that mC7 was
an integral membrane protein or was bound to ECs as a peripheral
membrane protein. To this end, HUVECs grown to confluence
were kept on ice in medium of progressively lower pH or high ionic
strength buffers for the maximal time compatible with their
survival (6 minutes), and the residual mC7 was measured by whole
cell ELISA. Both treatments failed to remove C7 from the cell
surface, suggesting that this C component was bound to the cell
membrane via relatively strong interactions (data not shown). The
possible binding of mC7 to the cell glycocalix was excluded,
because we failed to see any reduction in mC7 expression after the
treatment with a mixture of heparinases I, II, and III (Figure S1,
available on the Blood website; see the Supplemental Materials
link at the top of the online article) that remove cell-surface
glycosaminoglycans.
Analysis of cell-associated C7 extracted from HUVECs by
SDS-PAGE under reducing conditions, and Western blot analysis,
revealed a band of mC7 with an electrophoretic mobility similar to
that of C7 secreted by ECs or purified from human serum (Figure
3A) suggesting that the 3 molecules have the same molecular
weights. The structural similarity of soluble and mC7 was also
supported by the finding of one single message for C7 on Northern
blot analysis of mRNA extracted from HUVECs, that synthesize
both soluble and cell-bound C7. This band had an electrophoretic
mobility similar to the one obtained with HepG2 cells, that produce
only the soluble form of C7, and was specific because it was not
seen in the track containing mRNA from Raji cells that do not
synthesize this C component (Figure 3B,C).
To obtain further information on the molecular structure of
mC7, cell-bound C7 was purified by affinity chromatography and
analyzed by a MS-based shotgun proteomics approach.27 Tryptic
peptides spanning regions of the entire sequence of soluble C7
were identified (Table 1 and Table S1), with the exception of a
minor number of fragments either too long or too short to be
compatible with MS analysis. This result, together with the
electrophoretic mobility data, shows that mC7 is structurally
indistinguishable from soluble C7 and therefore excludes the
presence of transmembrane protein domains in mC7. Interestingly,
sequence analysis of the affinity-purified material from HUVECs
with an antibody to C7 revealed vimentin as a major contaminant
copurified with C7 (Table 1 and Table S1). The presence of
vimentin on the surface of HUVECs was documented by FACS
Figure 2. Expression of C7 on ECs of blood vessels in various tissues. Sections
of paraffin-embedded human skin, kidney, brain, endometrium, and decidua were
stained for C7 using goat IgG anti–human C7 or control IgG. Bound antibodies were
revealed with the LSAB horseradish peroxidase (HRP) kit and 3-amino-9-
ethylcarbazole (AEC) as chromogen. The sections were counterstained with hema-
toxylin. Magnification bar represents 30 m.
Figure 3. Characterization of mC7. (A) Western blot analysis of affinity-purified C7 from human normal serum (track 1), from cell supernatant (track 2), or from cell lysate
(track 3). (B) Northern blot analysis of mRNA purified from 2 preparations of HUVECs (track 1 and 2), HepG2 (positive control; track 3), and Raji cells (negative control; track 4).
(C) Ethidium bromide image of 2 preparations of HUVECs (track 1 and 2), HepG2 (track 3), and Raji cells (track 4). One of 3 experiments with similar results is shown.
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analysis on cells grown to confluence and detached with EDTA
(Figure 4A). The formation of a complex between C7 and vimentin
was confirmed by analysis of affinity purified mC7 by SDS-PAGE
under reducing conditions, followed by Western blot analysis,
using polyclonal antibodies to C7 and vimentin. As shown in
Figure 4B, the antibodies revealed 2 distinct bands corresponding
to vimentin (50 kDa) and C7 (105 kDa), respectively. Copurifica-
tion of vimentin with C7 was also supported by the immunoenzy-
matic analysis of the complex extracted from HUVECs. To this
purpose, cells grown to confluence were incubated with goat IgG
anti-C7 and then lysed with n-octyl pyranoside. The cell extract
containing IgG bound to surface-expressed C7 was added to wells
coated with Protein G to allow binding of IgG, and the presence of
vimentin in the complex was revealed by specific antibodies. The
results presented in Figure 4C clearly show that vimentin was
bound to mC7 forming a molecular complex. Similar experiments
were performed incubating the cells with goat IgG to C3 or C6, and
in both cases we failed to detect bound vimentin, suggesting that
this molecule interacts selectively with C7 and does not bind to C3,
C6, or IgG.
The molecular similarity of soluble and mC7 led us to
investigate the ability of cell-associated C7 to contribute to the
assembly of TCC. To address this issue, the cells were incubated
with C5b6, C8, and C9, and the formation of TCC on the cell
membrane (mTCC) was revealed using the mAb aE11 that
selectively recognizes a neoepitope on polymerized C9. Under
these conditions, TCC containing C9 dimers (Figure S2) was easily
assembled on mC7, and its formation was prevented by incubating
the cells with goat IgG anti-C7 before addition of C5b6 and the
remaining late components C8 and C9 (Figure 5A). To assess the
incorporation of S-protein and clusterin into mTCC, affinity
purified mC7 or soluble C7 were incubated with C5b6 and
C7-deficient serum (C7D), as a source of the remaining late C
components, S-protein, and clusterin. The results shown in Figure
5B indicate that both C regulators were incorporated both into
mTCC and soluble TCC as evaluated by ELISA using specific
antibodies.
The complex assembled on membrane C7 down-regulates the
proinflammatory effect of the soluble terminal complex
Previous data from our own group have shown that the cytolyti-
cally inactive complex is able to stimulate ECs inducing proinflam-
matory effects.15,16,18 This observation prompted us to ascertain
whether the TCC assembled on mC7 (mTCC) might have similar
stimulating activity on ECs. Titration curves were established to
find the concentrations of C5b6, C8, and C9 required for the
assembly of the maximal amount of mTCC on HUVECs as
assessed by the binding of mAb aE11. The mTCC formed under
these conditions was then evaluated for the ability to stimulate ECs
as compared with the activity of SC5b-9. As expected, SC5b-9 at
Table 1. Mass spectrometry–based proteomic analysis of affinity-purified C7
Homo sapiens (human)
Complement component C7
MKVISLFILVGFIGEFQSFSSASSPVNCQWDFYAPWSECNGCTKTQTRRRSVAVYGQYGGQPCVGNAFETQSCEPTRGCPTEEGCGERFRCFSGQCISKSLVCNGDS
DCDEDSADEDRCEDSERRPSCDIDKPPPNIELTGNGYNELTGQFRNRVINTKSFGGQCRKVFSGDGKDFYRLSGNVLSYTFQVKINNDFNYEFYNSTWSYVKHTST
EHTSSSRKRSFFRSSSSSSRSYTSHTNEIHKGKSYQLLVVENTVEVAQFINNNPEFLQLAEPFWKELSHLPSLYDYSAYRRLIDQYGTHYLQSGSLGGEYRVLFYVD
SEKLKQNDFNSVEEKKCKSSGWHFVVKFSSHGCKELENALKAASGTQNNVLRGEPFIRGGGAGFISGLSYLELDNPAGNKRRYSAWAESVTNLPQVIKQKLTPLY
ELVKEVPCASVKKLYLKWALEEYLDEFDPCHCRPCQNGGLATVEGTHCLCHCKPYTFGAACEQGVLVGNQAGGVDGGWSCWSSWSPCVQGKKTRSRECNNPP
PSGGGRSCVGETTESTQCEDEELEHLRLLEPHCFPLSLVPTEFCPSPPALKDGFVQDEGTMFPVGKNVVYTCNEGYSLIGNPVARCGEDLRWLVGEMHCQKIACV
LPVLMDGIQSHPQKPFYTVGEKVTVSCSGGMSLEGPSAFLCGSSLKWSPEMKNARCVQKENPLTQAVPKCQRWEKLQNSRCVCKMPYECGPSLDVCAQDERSK
RILPLTVCKMHVLHCQGRNYTLTGRDSCTLPASAEKACGACPLWGKCDAESSKCVCREASECEEEGFSICVEVNGKEQTMSECEAGALRCRGQSISVTSIRPCA
AETQ
Vimentin
MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGVYATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQ
ELNDRFANYIDKVRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNAS
LARLDLERKVESLQEEIAFLKKLHEEEIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSEAANRNNDALRQAKQESTEYRR
QVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLD
SLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE
Italicized, underlined text indicates portions removed after synthesis (Met/signal peptide). Bold, underlined text represents a sequence covered by MS analysis.
Figure 4. Membrane-bound C7 is anchored to vimentin on the cell surface.
(A) FACS analysis of nonpermeabilized HUVECs for surface expression of vimentin
using mAb anti-vimentin (black line) or unrelated IgG (gray line) (10 g/ml) followed
by RPE-labeled secondary antibody. (B) Western blot of C7 affinity-purified from cell
lysate analyzed with polyclonal anti-C7 (1:1000) (track 1) or anti-vimentin (1:100)
(track 2) followed by AP-conjugated anti–goat antibodies. (C) ECs were incubated
with goat IgG to C7, or with goat IgG to C3 or C6, as controls, and then lysed. The
expression of C7/vimentin complex in the cell lysate was documented by AC-ELISA
using protein G–coated wells to trap the complex containing antibodies to the
C components in the cell lysate and goat IgG anti-vimentin to reveal the presence of
this protein in the complex. The results are expressed as mean ( SD) of triplicate
determinations of 3 separate experiments. *P 	 .01 versus controls.
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the concentration of 5 g/mL was effective in inducing expression
of adhesion molecules, release of IL-8, and bovine serum albumin
(BSA) leakage on a monolayer of HUVECs, whereas mTCC failed
to do so (Figure 6A-C). Next, we examined the possibility that
assembly of mTCC on the cell surface before addition of SC5b-9
might control the stimulating effect induced by the soluble
complex. To this end, mTCC was allowed to assemble on a
confluent monolayer of ECs incubated with C5b6, C8, and C9 for
2 hours at 37°C, and the cells were then exposed to SC5b-9. Under
these conditions, SC5b-9 was still able to bind to mTCC-bearing
ECs, suggesting that mTCC does not prevent SC5b-9 binding (data
not shown). However, the stimulating activity of SC5b-9 was
totally inhibited and was not significantly different from that of
mTCC or medium alone (Figure 6A-C). To investigate if mC7
expression is altered at inflammatory sites, HUVECs were stimu-
lated with proinflammatory cytokines (IL-1, TNF-, and IFN-),
and the presence of mC7 was evaluated by ELISA. The results
(Figure S3) indicate that all these proinflammatory mediators
increased the expression of mC7 on the cell membrane. The
maximal inhibitory effect obtained with the full complex decreased
to 40 and 15% with the assembly of mC5b-8 and mC5b-7,
respectively, and was not seen when HUVECs were treated with
goat IgG anti-C7 (data not shown). Moreover, a concentration of
C5b6, C8, and C9 4-fold lower than that used for the assembly of
the highest amount of complex (Figure 7A) was still effective in
inhibiting the stimulatory activity of SC5b-9 suggesting that low
amount of mTCC was sufficient to down-regulate the proinflamma-
tory effect of SC5b-9 (Figure 7B).
Discussion
C7 is a critical component of the terminal pathway of C activation,
and its main function is to contribute to the formation of MAC and
the cytolytically inactive SC5b-9 involved in host defense against
pathogens and also in the promotion of inflammation. We have
previously reported that fluid-phase C7, the only late C component
Figure 5. mC7 retains the ability to participate in the assembly of the TCC.
(A) HUVECs grown to confluence in 96-well plates were incubated with the mixture of
C5b6, C8, and C9 in the absence or in the presence of polyclonal anti-C7 antibodies
(20 g/mL), or C5b6 and C9 as a negative control. The assembly of mTCC was
revealed by mAbs anti-C9 neoantigen. Values are mean ( SD) of triplicate
determinations of 3 separate experiments (*P 	 .05 vs complete cell culture
medium). (B) Analysis of SC5b-9 formed by incubating C5b6 with C7-deficient serum
(C7D) in the presence of either mC7 or soluble C7. The mixture of C5b6 and
C7-deficient serum in the absence of C7 served as control. The formation of the
complex was documented by ELISA using goat IgG anti-C5 as a capture reagent and
mAb aE11 to reveal exposure of C9 neoantigen. The presence of clusterin or
S-protein into the complex was evaluated as above except that mAbs anti-clusterin or
anti–S-protein were used as revealing reagents (**P 	 .01; *P 	 .05 vs control).
Figure 6. TCC assembled on mC7 down-regulates the proinflammatory effects
of SC5b-9. (A) Expression of adhesion molecules. HUVECs were stimulated with
SC5b-9 either alone or in the presence of the mTCC. The expression of the adhesion
molecules was evaluated by ELISA on whole cells using mAbs to vascular adhesion
molecule-1 (VCAM-1; 12 hours after stimulation), intercellular adhesion molecule-1
(ICAM-1), or E-selectin (both 4 hours after stimulation). Values are mean ( SD) of
triplicate determinations of 3 separate experiments (*P 	 .05 vs complete cell-
culture medium). (B) Synthesis of IL-8. The amount of IL-8 in supernatant of HUVECs
stimulated for 12 hours with SC5b-9, in the presence or in the absence of mTCC, or
TNF-, as a positive control, or complete cell-culture medium alone, was evaluated
by ELISA. One of 3 experiments with similar results is shown. (C) Endothelial leakage
assay. HUVECs grown to confluence on the insert of the Transwell were treated with
SC5b-9 in the presence or in the absence of mTCC. The FITC-BSA amount collected
in the lower chamber after 30 minutes was measured by the Infinte200 (Tecan,
Ma¨nnedorf, Switzerland). Values are mean ( SD) of triplicate determinations of
4 separate experiments (**P 	 .01 vs complete cell-culture medium).
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that is not synthesized in the liver,28 may have a regulatory function
restricting the assembly of the terminal complex.29 The data
presented in this paper suggest the possibility that C7 expressed on
the cell membrane has an additional role acting as a trap for the late
C components on ECs and as a regulator of the excessive
proinflammatory stimulation induced by SC5b-9.
An unexpected finding was that C7 was highly expressed on
the surface of ECs, while C3 was undetectable, although the 2 C
components are secreted by these cells at comparable levels.19
This observation was surprising, because all C components
including C7, with the exception of several C regulators and
receptors, circulate in the blood and are present in the extravas-
cular fluid as soluble molecules. The only other C component
recently shown to be synthesized by the ECs of decidual vessels
in human placenta and expressed on their surface is C1q, which
acts as a bridge between endovascular trophoblast and decidual
endothelial cells (DECs).20 However, the expression of C1q is
restricted to DECs in pregnancy, whereas C7 is more widely
distributed on ECs from various tissues, including skin, brain,
kidney, endometrium, and decidua, suggesting a physiologic
role for cell-bound C7 in vivo.
A possible explanation for the ability of ECs to secrete soluble C7
and to express this component on their surface is that the 2 molecules
may be, at least in part, structurally different. However, in this case, one
would expect 2 RNA messages in ECs, but the finding of one single
message for C7 in the Northern blot analysis pattern of mRNAextracted
from these cells ruled out this possibility, although we cannot exclude
relatively small differences between transcript sizes. This conclusion is
further supported by the observation that mC7 and soluble C7 examined
by SDS-PAGE under reducing conditions had the same electrophoretic
mobility suggesting that they also had similar molecular weights.
Analysis of mC7 by MS-based shotgun proteomics provided more
direct information on the molecular structure of this molecule suggest-
ing high similarity between soluble and membrane-associated C7.
These data indicate that mC7 is a peripheral membrane protein rather
than a transmembrane molecule. Failure of cells to release mC7 after
incubation in low pH or high ionic strength medium or after heparinase
treatment is compatible with a relatively strong interaction of this C7
component with the cell surface. In this regard, mC7 differs from mC1q,
because the latter is easily removed from the cell membrane under
similar experimental conditions.20
Unexpectedly, sequence analysis of mC7 revealed the presence of
vimentin that coprecipitated with this molecule during the purification
procedure. Vimentin is a major structural component of intermediate
filaments in many cell types and interacts with other cytoskeleton
proteins to promote cell contraction, migration, stiffness, and prolifera-
tion.30 The formation of a vimentin-mC7 complex was confirmed by the
detection of vimentin in C7 affinity-purified from the cell extract and
analyzed by SDS-PAGE and by a sandwich assay using an antibody to
C7 to trap mC7 and an antibody to vimentin to detect this protein in the
complex. Binding to vimentin was selective for C7 because we failed to
document complex formation of this intermediate filament molecule
with C3, that is also produced by ECs, or to C6, used as a control.
Although vimentin is regarded primarily as an intracellular protein, its
presence on the cell surface has been documented on tumor cells,31
lymphocytes,32 and ECs33 and has been confirmed in the present study
by FACS analysis of HUVECs. The finding that mC7 is not released
from the cell surface by lowering the pH or by increasing the ionic
strength of the buffer suggests that mC7 establishes a strong interaction
with vimentin, although the 2 molecules can be dissociated from the
complex under reducing conditions.
Since membrane-bound and soluble C7 share a similar molecular
structure, the question arises whether the cell-associated molecule is
captured from the medium after secretion. Failure of C7 added to the
culture medium to bind to EC surface tends to exclude this possibility
and rather supports the concept that this C component is placed on the
cell surface during biosynthesis. Vimentin found to coimmunoprecipi-
tate with mC7 extracted from EC membrane with antibody to C7 is
likely to provide the binding site for this C component. This conclusion
is supported by the finding that C7 is highly expressed on the cell
membrane only when the cells reorganize vimentin along the surface
after reaching confluence.34 Soluble C7 is also released by ECs after
reaching confluence19 and is likely to represent the portion of synthe-
sized C7 unbound to vimentin.
Cell-associated C7 maintains the ability to bind C5b6, C8,
and C9, forming mTCC on the cell surface, as shown by ELISA.
The complex assembled on ECs is cytolytically inactive and
contains S-protein and clusterin resembling soluble SC5b-9.
The conditions in which mTCC may be formed are acute
situations, such as sepsis, associated with unrestricted C activa-
tion leading to the release of C activation products, including
SC5b-9.35 Excessive C activation is also responsible for the
consumption of C7 and the generation of activated C5b6 from
the acute phase proteins C5 and C6.36 The C5b6 complex
produced in excess is then available for mC7 and initiates the
assembly of the full complex on the cell surface.
Data collected over the last 2 decades have provided
evidence for the ability of cytolytically inactive TCC to
stimulate the expression of adhesion molecules,7 to induce the
release of IL-8,37 and also to promote vascular leakage.16 This is
Figure 7. Low amount of mTCC was sufficient to down-regulate the proinflamma-
tory effect of SC5b-9. (A) mTCC was assembled on mC7 incubating HUVECs with
increasing amount of C5b-6 (0.5 g [a], 1 g [b], 2 g [c], and 3 g [d] to a final volume of
100 L). C8 and C9 were added to C5b6 at a molar ratio of 1:2:2, respectively. The
assembly of mTCC was revealed by ELISA on whole cells using anti-C9 neoantigen.
(B) HUVECs were stimulated with SC5b-9 (5 g/mL) either alone or in the presence of
mTCC assembled using the same quantity of C5b6, C8, and C9 as used above. The
expression of VCAM-1 was evaluated by ELISAon whole cells as indicated in the legend to
Figure 6A. Values are mean ( SD) of triplicate determinations of 3 separate experiment
(*P	 .05; **P	 .01 vs complete cell-culture medium).
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not the case of the complex assembled on mC7, that proved to be
totally ineffective in this respect. The failure of mTCC to
stimulate ECs may be attributed to the type of interaction
that the complex establishes with the cell membrane. While
mTCC is assembled on cell-bound C7 that acts as a trap for the
other components, soluble SC5b-9 binds to ECs through both
S protein38 and polymerized C9.18
We were surprised to find out that mTCC not only failed to
activate the cells, but also down-regulated the activation signal of
SC5b-9 resulting in reduced expression of adhesion molecules,
release of IL-8, and endothelial cell permeability. The inability of
goat IgG anti-C7 to induce an inhibitory effect suggests that the
activity of mTCC as a down-regulator does not depend solely on
C7. C9 plays a critical role since the inhibition obtained with
mC5b-8 was only 40% that of mTCC and further decreased to
approximately 15% with mC5b-7 suggesting also the involvement
of C8. The contribution of vimentin to this effect is unclear, but
published data suggest that vimentin may act as a potential
regulator of transcription, interacting and sequestering transcrip-
tional determinants such as p5339 and menin.40
SC5b-9 released in limited amount at the inflammatory site after
local C activation is beneficial and promotes inflammation. Con-
versely, excessive amount of circulating SC5b-9 formed as a result
of unrestricted C activation in patients with sepsis and other acute
phase situations can be harmful. These are the conditions that favor
the formation of free C5b613 and in which mC7 may act as a
trapping molecule promoting the assembly of mTCC preventing in
this way the damaging effect of SC5b-9. A point to emphasize is
that CD59 expressed on ECs efficiently prevents the assembly of
MAC, but has no effect on SC5b-9, that can only be controlled by
mTCC. Interestingly, the protective activity of mTCC does not
require high concentration of C5b6, C8, and C9 and can still be
seen with a relatively low amount of C components.
In conclusion, we have shown that ECs express surface C7
bound to vimentin as a trapping molecule for the assembly of
mTCC. This complex does not induce activation of ECs, but rather
down-regulates the pro-inflammatory effect of circulating SC5b-9.
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